LeMaitre Vascular (NASDAQ:LMAT) Updates FY 2025 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 2.150-2.320 for the period, compared to the consensus estimate of 2.160. The company issued revenue guidance of $235.4 million-$242.8 million, compared to the consensus revenue estimate of $240.2 million. LeMaitre Vascular also updated its Q1 2025 guidance to 0.480-0.530 EPS.

Wall Street Analyst Weigh In

LMAT has been the topic of a number of recent analyst reports. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday. Oppenheimer cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Wells Fargo & Company initiated coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and an average price target of $94.63.

LeMaitre Vascular Stock Down 11.8 %

LMAT opened at $90.87 on Friday. The business has a fifty day simple moving average of $96.90 and a 200-day simple moving average of $94.66. The firm has a market cap of $2.04 billion, a PE ratio of 49.01, a P/E/G ratio of 2.22 and a beta of 0.96. LeMaitre Vascular has a fifty-two week low of $62.39 and a fifty-two week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.49. The business had revenue of $55.81 million during the quarter, compared to analyst estimates of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. On average, equities research analysts anticipate that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.